| Kywoa Hakko and Lonza extend collaboration | Posted on 15/07/2008 in Pharmaceutical Company Product News Lonza and Kyowa Hakko Kogyo have announced an extension to their strategic partnership agreement.
Under the terms of the extended agreement, Konza will license its GS (glutamine synthetase) Gene Expression System to Kyowa Hakko and its BioWa subsidiary.
Prior to the extension of this agreement, Lonza and BioWad had previously partnered to combine the GS Gene Expression System with the Potelligent technology from Kyowa Hakko.
Kywo Hakko is able to use the GS Gene Expression System and Potelligent technology as a platform for the production of recombinant proteins and antibodies being developed by the firm.
Dr Stephan Kutzer, head of Lonza Biopharmaceuticals, said the company was pleased to widen its strategic partnership with Kyowa Hakko.
"As a leader in their field, we believe that having Kyowa Hakko Group select the GS Gene Expression System underscores the success and importance of this technology for the efficient production of therapeutic antibodies and recombinant proteins," he added.
Dr Nobuo Hanai, managing officer and head of the pharmaceutical research and development division of Kyowa Hakko said the partnership could potentially boost its production system for biological drugs.
In March 2008, Kyowa Hakko signed an agreement with Amgen to exclusively develop and commercialise its humanised monoclonal antibodies.Other news stories from 15/07/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
